Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131297 | 0.76 | GAA (0.57) | POLBKMT2AGAASMN1; SMN2 | |
| SCHEMBL26131295 | 0.76 | GAA (0.57) | POLBKMT2AGAASMN1; SMN2 | |
| SCHEMBL11814665 | 0.75 | EPHX2 (0.46) | EPHX2GAAALDH1A1APPHCAR3 | |
| SCHEMBL27870261 | 0.74 | NPC1 (0.61) | EPHX2PTGS2POLBKMT2AALDH1A1 | |
| SCHEMBL30573569 | 0.74 | NPC1 (0.61) | EPHX2PTGS2POLBKMT2AALDH1A1 | |
| SCHEMBL2762731 | 0.73 | CES2 (0.53) | RAB9ANPC1 | |
| SCHEMBL4978745 | 0.73 | SLC6A9 (0.56) | POLBKMT2AGAAALDH1A1MAPK1 | |
| SCHEMBL6654487 | 0.73 | KMT2A (0.54) | EPHX2PTGS2POLBKMT2AATM | |
| SCHEMBL28457962 | 0.72 | TDP1 (0.55) | EPHX2ATMGAAALDH1A1RAB9A | |
| SCHEMBL16164843 | 0.72 | HDAC3 (0.46) | KMT2AGAAALDH1A1NPC1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1899320-B1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KV1 .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1899320-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136305-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | KCNH1, MLLT3, CYP1A2 | EPHX2 1285/4885PTGS2 943/4885POLB 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.